BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 17054793)

  • 1. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
    Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG
    Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis.
    Jankowski J; Hopwood D; Pringle R; Wormsley KG
    Am J Gastroenterol; 1993 Mar; 88(3):402-8. PubMed ID: 8438848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett's esophagus with antireflux surgery.
    Oh DS; DeMeester SR; Vallbohmer D; Mori R; Kuramochi H; Hagen JA; Lipham J; Danenberg KD; Danenberg PV; Chandrasoma P; DeMeester TR
    Arch Surg; 2007 Jun; 142(6):554-9; discussion 559-60. PubMed ID: 17576892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
    Konturek PC; Kania J; Burnat G; Hahn EG
    J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
    Soslow RA; Remotti H; Baergen RN; Altorki NK
    Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
    BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.
    Swami S; Kumble S; Triadafilopoulos G
    Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
    Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
    Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
    Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.